Although there is no clear evidence of the crosstalk between miR-130a and the mTOR pathway during DR, it is noteworthy that miR-130a is a negative regulator of TSC1, capable of upregulating the mTOR pathway in high-grade serous ovarian carcinoma (129). This evidence concerns the gene MTOR and ovarian serous carcinoma.